BNTC — Benitec Biopharma Inc.

BNTC closed at $8.68 (+1.05%) on Oct 27, 2026. Active shelf registration (S-3, Sep 2026). Float: 21.1M shares. Latest SEC filing: 8-K on Oct 28, 2026.

Opening the full analysis uses 1 of your 3 free tickers today.

Open full analysis

Chart, dilution, float and news for BNTC in the TickerWise workspace.

Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy; and BB-103 for the treatment of chronic hepatitis B virus infection. The company was incorporated in 1995 and is headquartered in Hayward, California.

Company profile

• Sector: Healthcare
• Industry: Biotechnology
• Country: US
• Exchange: NASDAQ
• Employees: 16
• Website: https://benitec.com

Latest SEC filings for BNTC

• 2026-10-288-K
• 2026-09-22EFFECT
• 2026-09-14S-3
• 2026-05-1410-Q
• 2026-05-148-K
• 2026-03-2010-K/A
• 2026-02-128-K
• 2026-02-1210-Q
• 2026-02-11424B3
• 2026-01-30S-3

Latest BNTC news

• 2026-10-05Benitec Biopharma Announces Regulatory Update Following Type C Meeting with FDA for BB-301 Pivotal Study Read article

Related companies

• VRTX — Vertex Pharmaceuticals Incorporated
• MRNA — Moderna, Inc.
• REGN — Regeneron Pharmaceuticals, Inc.
• ARGX — argenx SE
• ALNY — Alnylam Pharmaceuticals, Inc.
• INSM — Insmed Incorporated
• RVMD — Revolution Medicines, Inc.
• UTHR — United Therapeutics Corporation

Opening the full analysis uses 1 of your 3 free tickers today.

Open full analysis

Educational tool only — not investment advice.